{"generic":"Rifabutin","drugs":["Mycobutin","Rifabutin"],"mono":{"0":{"id":"516100-s-0","title":"Generic Names","mono":"Rifabutin"},"1":{"id":"516100-s-1","title":"Dosing and Indications","sub":[{"id":"516100-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Disseminated infection due to Mycobacterium avium-intracellulare group; Prophylaxis - HIV infection:<\/b> (primary prevention) 300 mg ORALLY once daily<\/li><li><b>Disseminated infection due to Mycobacterium avium-intracellulare group; Prophylaxis - HIV infection:<\/b> (secondary prevention) 300 mg ORALLY daily in combination with clarithromycin 500 mg ORALLY twice daily and ethambutol 15 mg\/kg ORALLY daily<\/li><li><b>Disseminated infection due to Mycobacterium avium-intracellulare group - HIV infection:<\/b> 300 mg ORALLY daily in combination with clarithromycin 500 mg ORALLY twice daily and ethambutol 15 mg\/kg ORALLY daily<\/li><li><b>HIV infection - Tuberculosis:<\/b> 150 mg ORALLY once daily OR 300 mg ORALLY 3 times weekly in combination with amprenavir, indinavir or nelfinavir<\/li><li><b>HIV infection - Tuberculosis:<\/b> 150 mg ORALLY every other day OR 150 mg ORALLY 3 times weekly in combination with ritonavir<\/li><li><b>HIV infection - Tuberculosis:<\/b> 450 mg ORALLY once daily OR 600 mg ORALLY 3 times weekly in combination with efavirenz<\/li><li><b>HIV infection - Tuberculosis:<\/b> 150 mg ORALLY every other day OR 150 mg ORALLY 3 times weekly in combination with saquinavir\/ritonavir<\/li><li><b>HIV infection - Tuberculosis:<\/b> 300 mg ORALLY once daily OR 300 mg ORALLY 3 times weekly in combination with nevirapine<\/li><li><b>Mycobacterium avium complex infection, Lung disease:<\/b> (severe or previously treated disease) rifabutin 150 to 300 mg ORALLY daily in combination with clarithromycin 1000 mg ORALLY daily (or 500 mg twice daily) OR azithromycin 250 mg ORALLY daily plus ethambutol 15 mg\/kg ORALLY daily plus streptomycin OR amikacin<\/li><\/ul>"},{"id":"516100-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>safety and efficacy have not been established<\/li><li><b>Disseminated infection due to Mycobacterium avium-intracellulare group; Prophylaxis - HIV infection:<\/b> (primary prevention) 6 yr and older, 300 mg ORALLY daily<\/li><li><b>Disseminated infection due to Mycobacterium avium-intracellulare group; Prophylaxis - HIV infection:<\/b> (secondary prevention) 5 mg\/kg ORALLY daily (MAX 300 mg\/day) in combination with clarithromycin 7.5 mg\/kg ORALLY twice daily (MAX 500 mg twice daily) and ethambutol 15 to 25 mg\/kg ORALLY daily (MAX 2.5 g\/day)<\/li><li><b>Disseminated infection due to Mycobacterium avium-intracellulare group - HIV infection:<\/b> (severe disease) 10 to 20 mg\/kg ORALLY once daily (MAX 300 mg\/day) in combination with clarithromycin 7.5 to 15 mg\/kg ORALLY twice daily (MAX 500 mg twice daily) and ethambutol 15 to 25 mg\/kg ORALLY once daily (MAX 2.5 g\/day)<\/li><\/ul>"},{"id":"516100-s-1-6","title":"Dose Adjustments","mono":"<b>renal impairment:<\/b> 50% dose reduction for severe renal impairment (CrCl less than 30 mL\/min) "},{"id":"516100-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Disseminated infection due to Mycobacterium avium-intracellulare group; Prophylaxis - HIV infection<br\/><b>Non-FDA Labeled Indications<\/b><ul><li>Atypical mycobacterial infection<\/li><li>Crohn's disease<\/li><li>Disseminated infection due to Mycobacterium avium-intracellulare group - HIV infection<\/li><li>Helicobacter pylori gastrointestinal tract infection<\/li><li>HIV infection - Tuberculosis<\/li><li>Mycobacterium avium complex infection, Lung disease<\/li><li>Tuberculosis<\/li><li>Tuberculosis, Extrapulmonary<\/li><\/ul>"}]},"3":{"id":"516100-s-3","title":"Contraindications\/Warnings","sub":[{"id":"516100-s-3-9","title":"Contraindications","mono":"<ul><li>Concomitant use with delavirdine<\/li><li>Concomitant use with rilpivirine<\/li><li>Concomitant use with voriconazole<\/li><li>Hypersensitivity to rifabutin or to any other rifamycins<\/li><\/ul>"},{"id":"516100-s-3-10","title":"Precautions","mono":"<ul><li>Gastrointestinal:<\/li><li>-- Clostridium difficile-associated diarrhea, including mild diarrhea to fatal colitis, has been reported and may occur over 2 months from last dose; discontinue use if suspected<\/li><li>Hematologic:<\/li><li>-- Neutropenia has been reported; monitoring recommended<\/li><li>-- Thrombocytopenia has been reported; monitoring recommended<\/li><li>Immunologic:<\/li><li>-- Not recommended in patients with known active TB; may lead to TB that is resistant to rifabutin and rifampin<\/li><li>Ophthalmic:<\/li><li>-- Uveitis may occur; monitoring recommended during concurrent use of macrolide antibiotic or fluconazole and related compounds; interruption may be necessary<\/li><li>Concomitant Use:<\/li><li>-- Etravirine when used in combination with a ritonavir-boosted protease inhibitor; avoid use<\/li><li>-- Cobicistat\/elvitegravir\/emtricitabine\/tenofovir is not recommended<\/li><\/ul>"},{"id":"516100-s-3-11","title":"Pregnancy Category","mono":"<ul><li>B (FDA)<\/li><li>C (AUS)<\/li><\/ul>"},{"id":"516100-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"516100-s-4","title":"Drug Interactions","sub":[{"id":"516100-s-4-13","title":"Contraindicated","mono":"<ul><li>Artemether (theoretical)<\/li><li>Daclatasvir (theoretical)<\/li><li>Delamanid (theoretical)<\/li><li>Isavuconazonium Sulfate (theoretical)<\/li><li>Lumefantrine (theoretical)<\/li><li>Lurasidone (probable)<\/li><li>Maraviroc (theoretical)<\/li><li>Paritaprevir (theoretical)<\/li><li>Ranolazine (theoretical)<\/li><li>Voriconazole (probable)<\/li><\/ul>"},{"id":"516100-s-4-14","title":"Major","mono":"<ul><li>Abiraterone (theoretical)<\/li><li>Amprenavir (probable)<\/li><li>Apixaban (theoretical)<\/li><li>Apremilast (theoretical)<\/li><li>Aripiprazole (theoretical)<\/li><li>Atazanavir (probable)<\/li><li>Axitinib (theoretical)<\/li><li>Bedaquiline (theoretical)<\/li><li>Boceprevir (theoretical)<\/li><li>Bortezomib (theoretical)<\/li><li>Bosutinib (theoretical)<\/li><li>Cabozantinib (theoretical)<\/li><li>Carbamazepine (theoretical)<\/li><li>Ceritinib (theoretical)<\/li><li>Clarithromycin (established)<\/li><li>Clozapine (theoretical)<\/li><li>Cobicistat (theoretical)<\/li><li>Crizotinib (theoretical)<\/li><li>Cyclosporine (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Darunavir (established)<\/li><li>Dasatinib (theoretical)<\/li><li>Delavirdine (probable)<\/li><li>Donepezil (theoretical)<\/li><li>Doxorubicin (theoretical)<\/li><li>Doxorubicin Hydrochloride Liposome (theoretical)<\/li><li>Efavirenz (established)<\/li><li>Eliglustat (theoretical)<\/li><li>Elvitegravir (theoretical)<\/li><li>Enzalutamide (theoretical)<\/li><li>Erlotinib (theoretical)<\/li><li>Eslicarbazepine Acetate (theoretical)<\/li><li>Etravirine (probable)<\/li><li>Everolimus (theoretical)<\/li><li>Exemestane (established)<\/li><li>Fentanyl (theoretical)<\/li><li>Fluconazole (established)<\/li><li>Fosamprenavir (established)<\/li><li>Hydrocodone (theoretical)<\/li><li>Ibrutinib (theoretical)<\/li><li>Idelalisib (theoretical)<\/li><li>Ifosfamide (theoretical)<\/li><li>Indinavir (probable)<\/li><li>Irinotecan (theoretical)<\/li><li>Itraconazole (probable)<\/li><li>Ivabradine (theoretical)<\/li><li>Ivacaftor (theoretical)<\/li><li>Ixabepilone (theoretical)<\/li><li>Ketoconazole (theoretical)<\/li><li>Lapatinib (theoretical)<\/li><li>Ledipasvir (theoretical)<\/li><li>Linagliptin (theoretical)<\/li><li>Lopinavir (established)<\/li><li>Macitentan (theoretical)<\/li><li>Mifepristone (theoretical)<\/li><li>Mitotane (theoretical)<\/li><li>Naloxegol (theoretical)<\/li><li>Nelfinavir (established)<\/li><li>Netupitant (theoretical)<\/li><li>Nifedipine (probable)<\/li><li>Nilotinib (theoretical)<\/li><li>Olaparib (theoretical)<\/li><li>Palbociclib (theoretical)<\/li><li>Panobinostat (theoretical)<\/li><li>Pazopanib (theoretical)<\/li><li>Perampanel (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><li>Pomalidomide (theoretical)<\/li><li>Ponatinib (established)<\/li><li>Posaconazole (probable)<\/li><li>Primidone (theoretical)<\/li><li>Quetiapine (theoretical)<\/li><li>Regorafenib (theoretical)<\/li><li>Rilpivirine (established)<\/li><li>Ritonavir (established)<\/li><li>Romidepsin (theoretical)<\/li><li>Saquinavir (established)<\/li><li>Siltuximab (theoretical)<\/li><li>Sofosbuvir (theoretical)<\/li><li>Sorafenib (probable)<\/li><li>Sunitinib (theoretical)<\/li><li>Tacrolimus (theoretical)<\/li><li>Tasimelteon (theoretical)<\/li><li>Telaprevir (theoretical)<\/li><li>Temsirolimus (theoretical)<\/li><li>Tipranavir (established)<\/li><li>Tofacitinib (theoretical)<\/li><li>Tolvaptan (theoretical)<\/li><li>Trabectedin (theoretical)<\/li><li>Ulipristal (theoretical)<\/li><li>Vandetanib (theoretical)<\/li><li>Vemurafenib (theoretical)<\/li><li>Vilazodone (theoretical)<\/li><li>Vincristine (theoretical)<\/li><li>Vincristine Sulfate Liposome (theoretical)<\/li><li>Vinflunine (theoretical)<\/li><li>Vorapaxar (theoretical)<\/li><li>Vortioxetine (theoretical)<\/li><\/ul>"},{"id":"516100-s-4-15","title":"Moderate","mono":"<ul><li>Atovaquone (probable)<\/li><li>Azithromycin (probable)<\/li><li>Dapsone (probable)<\/li><li>Desogestrel (probable)<\/li><li>Didanosine (established)<\/li><li>Dienogest (probable)<\/li><li>Drospirenone (probable)<\/li><li>Estradiol Cypionate (probable)<\/li><li>Estradiol Valerate (probable)<\/li><li>Ethinyl Estradiol (probable)<\/li><li>Ethynodiol Diacetate (probable)<\/li><li>Etonogestrel (probable)<\/li><li>Imatinib (probable)<\/li><li>Levonorgestrel (probable)<\/li><li>Medroxyprogesterone Acetate (probable)<\/li><li>Mestranol (probable)<\/li><li>Nevirapine (established)<\/li><li>Norelgestromin (probable)<\/li><li>Norethindrone (probable)<\/li><li>Norgestimate (probable)<\/li><li>Norgestrel (probable)<\/li><li>Ospemifene (established)<\/li><li>Sirolimus (probable)<\/li><li>Sulfamethoxazole (probable)<\/li><li>Trimetrexate (probable)<\/li><li>Warfarin (probable)<\/li><li>Zidovudine (probable)<\/li><\/ul>"}]},"5":{"id":"516100-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Rash (11%)<\/li><li><b>Gastrointestinal:<\/b>Clostridium difficile diarrhea, Loss of taste<\/li><li><b>Ophthalmic:<\/b>Ocular discoloration, Uveitis<\/li><li><b>Renal:<\/b>Discolored urine (30%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Hematologic:<\/b>Neutropenia (25%), Thrombocytopenia (5%)<\/li><li><b>Immunologic:<\/b>Systemic lupus erythematosus<\/li><\/ul>"},"6":{"id":"516100-s-6","title":"Drug Name Info","sub":{"0":{"id":"516100-s-6-17","title":"US Trade Names","mono":"Mycobutin<br\/>"},"2":{"id":"516100-s-6-19","title":"Class","mono":"<ul><li>Antitubercular<\/li><li>Rifamycin<\/li><\/ul>"},"3":{"id":"516100-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"516100-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"516100-s-7","title":"Mechanism Of Action","mono":"Systemic: The antimicrobial activity of rifabutin is produced by inhibition of DNA-dependent RNA polymerase and subsequent initiation of transcription . This results in inhibition of protein synthesis . Rifabutin has a broad spectrum of antimicrobial activity . This includes activity against mycobacteria (atypical mycobacteria, including the Mycobacterium avium  complex [MAC],  Mycobacterium leprae, and  Mycobacterium tuberculosis), a variety of gram-positive and gram-negative bacteria,  Chlamydia trachomatis, and  Toxoplasma gondii    .<br\/>"},"8":{"id":"516100-s-8","title":"Pharmacokinetics","sub":[{"id":"516100-s-8-23","title":"Absorption","mono":"Systemic: Readily absorbed; high fat food slows absorption <br\/>"},{"id":"516100-s-8-24","title":"Distribution","mono":"Systemic: Vd: 9.3  plus or minus  1.5 L\/kg  <br\/>"},{"id":"516100-s-8-25","title":"Metabolism","mono":"Systemic: Hepatic <br\/>"},{"id":"516100-s-8-26","title":"Excretion","mono":"<ul><li>Systemic: 30% fecal; 5% unchanged in the urine; 5% unchanged in the bile; 53% in urine as metabolites .<\/li><li>In dialysis-Hemodialysis is not expected to enhance elimination .<\/li><li>Systemic: Fecal: 30%, 5% unchanged; Renal: 53% metabolites, 5% unchanged <\/li><\/ul>"},{"id":"516100-s-8-27","title":"Elimination Half Life","mono":"Systemic: 45 h (range 16 to 69) <br\/>"}]},"9":{"id":"516100-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/>take with or without food <br\/>"},"10":{"id":"516100-s-10","title":"Monitoring","mono":"<ul><li>Prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV is indicative of efficacy<\/li><li>CBC  with differential<\/li><li>Signs and symptoms of uveitis, especially with coadministration of macrolides antibiotics or fluconazole and related compounds<\/li><\/ul>"},"11":{"id":"516100-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/>Oral Capsule: 150 MG<br\/><\/li><li><b>Mycobutin<\/b><br\/>Oral Capsule: 150 MG<br\/><\/li><\/ul>"},"12":{"id":"516100-s-12","title":"Toxicology","sub":[{"id":"516100-s-12-31","title":"Clinical Effects","mono":"<b>RIFABUTIN <\/b><br\/>OVERDOSE: Overdose information is limited.  Daily doses of 1 g or greater have resulted in a syndrome of arthralgia\/arthritis. ADVERSE EFFECTS: Uveitis, rash and skin and urine discoloration have been frequently reported with rifabutin therapy.  Other reported adverse effects include neutropenia, leukopenia, thrombocytopenia, nausea, vomiting, dyspepsia, ageusia, anorexia, diarrhea and flatulence.<br\/>"},{"id":"516100-s-12-32","title":"Treatment","mono":"<b>RIFABUTIN <\/b><br\/><ul><li>Support: Treatment is symptomatic and supportive.<\/li><li>Decontamination: Activated charcoal.<\/li><li>Myelosuppression: Leukopenia, neutropenia and thrombocytopenia have been reported with therapeutic use but not after overdose. Filgrastim: 5 mcg\/kg\/day IV or subQ. Sargramostim: 250 mcg\/meter(2)\/day IV over 4 hours; transfusions of packed red blood cells and platelets may be useful if bleeding occurs.<\/li><li>Monitoring of patient: Monitor CBC with differential, liver enzyme levels and fluid\/electrolyte status in symptomatic patients.<\/li><li>Enhanced elimination procedure: Rifabutin is highly protein-bound and is extensively distributed into tissues; therefore, enhanced elimination techniques, including hemodialysis, hemoperfusion or forced diuresis, are not expected to be of any benefit following overdose.<\/li><\/ul>"},{"id":"516100-s-12-33","title":"Range of Toxicity","mono":"<b>RIFABUTIN <\/b><br\/>TOXICITY: A specific toxic dose has not been established.  A syndrome of arthralgia\/arthritis has been reported following daily doses of at least 1 g. THERAPEUTIC: ADULT - 150 to 300 mg\/day.<br\/>"}]},"13":{"id":"516100-s-13","title":"Clinical Teaching","mono":"<ul><li>Warn patient that drug may cause brown-orange discoloration of fluids\/tissues (skin, urine, feces, sputum, tears, and sweat) and permanently stain soft contact lenses.<\/li><li>Drug may cause rash, diarrhea, taste changes, dyspepsia, or nausea.<\/li><li>Advise patient to immediately report signs\/symptoms of active tuberculosis or mycobacterium avium complex disease (persistent cough, hemoptysis, fever, chills, weight loss, weakness, fatigue, chest pain, or night sweats).<\/li><li>Instruct patient to immediately report signs\/symptoms of Clostridium difficile-associated diarrhea (watery or bloody diarrhea, with or without fever) during or after discontinuation.<\/li><li>Advise patient, if prone to nausea, to take with food.<\/li><li>Advise patient there are multiple drug-drug interactions for this drug. Consult a healthcare professional prior to new drug use (including over-the-counter and herbal drugs).<\/li><\/ul>"}}}